Darrin Beaupre, MD, PhD, CMO
Biosplice Therapeutics, Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Darrin Beaupre, MD, PhD, CMO as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:38 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05084859 · A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid TumorsBiosplice Therapeutics, Inc. · terminated · Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer, Colorectal Cancer · study chair
- Ph1NCT03355066 · A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid TumorsBiosplice Therapeutics, Inc. · terminated · Solid Tumor, Adult · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:38 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.